Dexcom adds Ascensia’s glucose meter to CGM bundle

dexcom g5 system including cell phone and app
While data from the Dexcom G5 CGM system is used to inform treatment decisions, the system must be calibrated regularly. (Dexcom)

Dexcom and Ascensia Diabetes Care have struck a deal to provide the latter’s blood glucose meter as part of the former’s continuous glucose monitoring system for patients covered by Medicare.

The bundle, which comprises Ascensia’s Contour Next One blood glucose monitoring system and Dexcom’s G5 CGM system, is now available for patients under Medicare who are eligible for therapeutic glucose monitoring, according to a statement.

While glucose meters require a fingerprick to measure blood glucose, CGMs measure glucose levels in the interstitial fluid through a sensor inserted just under the skin. The Dexcom G5 system transmits glucose data to a smartphone or smartwatch every five minutes, where patients may view their glucose data trends.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Patients using the G5 system must calibrate it regularly to ensure the CGM sensor reading is “on track,” Ascensia said in the statement. Patients will use the Contour Next One system to calibrate the G5 system.

RELATED: Continuous glucose monitors get one step closer to Medicare coverage

While several CGMs are available on the market, including systems from Medtronic and Abbott, Dexcom’s G5 is the only one that is FDA-approved as a therapeutic device. The other systems are approved as adjunctive devices; the information they provide must be used alongside data from other devices, such as blood glucose monitors.

In March, the Centers for Medicare & Medicaid Services released coverage criteria for therapeutic CGMs. To be eligible for a therapeutic CGM, patients must have diabetes, use a home blood glucose monitor to test their glucose levels frequently, be treated with an insulin pump or multiple daily injections of insulin, and need to frequently adjust their insulin therapy based on data from a therapeutic CGM.

Suggested Articles

By employing heart rate signals, physical activity and sleep quality, common Fitbit trackers may be able to predict the spread of the flu.

Nanox has raised $26 million to help fuel the development and commercialization of its Star Trek-inspired digital X-ray bed.

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.